Filtered By:
Condition: Stroke
Procedure: Dialysis
This page shows you your search results in order of date. This is page number 20.
Order by Relevance | Date
Total 2903 results found since Jan 2013.
The Impact of Complete Revascularization in Symptomatic Severe Left Ventricular Dysfunction between Coronary Artery Bypass Graft and Percutaneous Coronary Intervention
CONCLUSIONS: In patients with symptomatic (NYHA class ≥ 3) severe LV dysfunction and CAD, CABG brought less HF admission when compared to patients in the PCI group, but this did not differ when compared to the complete revascularization subgroup. Therefore, an extensive revascularization, achieved by CABG or PCI, is associated with a lower HF hospitalization rate during the 3-yearfollow-up period in such populations.PMID:36896424 | PMC:PMC9991473 | DOI:10.1155/2023/9226722
Source: Cardiology Research and Practice - March 10, 2023 Category: Cardiology Authors: Hsiu-Yu Fang Yen-Nan Fang Yin-Chia Chen Jiunn-Jye Sheu Wei-Chieh Lee Source Type: research
Differences in major limb outcomes by indication for lower extremity endovascular revascularization in patients receiving hemodialysis
This study is to determine whether indication of PAD has a distinct impact on major adverse cardiovascular and cerebrovascular events (MACCE) and limb events in patients receiving hemodialysis. The current study included 2321 prospectively enrolled patients from the Tokyo taMA peripheral vascular intervention research ComraDE registry (UMIN-CTR no. UMIN000015100) between September 2014 and December 2016. Out of the enrolled patients, 1644 were not receiving hemodialysis (non-HD patients) and 603 were receiving hemodialysis (HD patients). A composite of all-cause death, myocardial infarction, and stroke events defined as MA...
Source: Heart and Vessels - March 6, 2023 Category: Cardiology Source Type: research
Minimally Invasive Mitral Valve Surgery in the Elderly
CONCLUSION: miMVS results in satisfactory early postoperative outcomes in elderly patients.PMID:36858067 | DOI:10.1055/s-0043-1762940
Source: The Thoracic and Cardiovascular Surgeon - March 1, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Maximilian Franz Nunzio Davide De Manna Saskia Schulz Fabio Ius Axel Haverich Serghei Cebotari Igor Tudorache Jawad Salman Source Type: research
SGLT2 Inhibitors: The Next Blockbuster Multifaceted Drug?
Medicina (Kaunas). 2023 Feb 16;59(2):388. doi: 10.3390/medicina59020388.ABSTRACTSodium glucose cotransporter 2 inhibitor (SGLT2i) is a class of drugs that were originally intended for decreasing blood glucose in diabetes. However, recent trials have shown that there are other beneficial effects. Major clinical trials involving SGLT2i medications from 2015 to 2022 were reviewed using PUBMED search. Recent major SGLT2i landmark trials have demonstrated benefits for cardiovascular disease (reduce major adverse cardiovascular events (heart attack, stroke, cardiovascular death), hospitalization for heart failure, all-cause deat...
Source: Medicina (Kaunas) - February 25, 2023 Category: Universities & Medical Training Authors: Jonathan C H Chan Michael C Y Chan Source Type: research
Risk of Major Cardiovascular Disease after Exposure to Contrast Media: A Nationwide Population-Based Cohort Study on Dialysis Patients
Metabolites. 2023 Feb 13;13(2):266. doi: 10.3390/metabo13020266.ABSTRACTContrast associated kidney injury is caused by side effects of iodinated contrast media (ICM), including inflammation. Chronic inflammation among dialysis patient contributes to atherosclerosis, which leads to simultaneous conditions of the kidney, brain, and vasculature. Data to investigate the pathologic effects of ICM on cardiovascular complications in dialysis patients are lacking. Dialysis patients who had been exposed to ICM from computed tomography (ICM-CT) were allocated as the ICM-CT cohort (N = 3751), whereas dialysis patients without ICM exp...
Source: Atherosclerosis - February 25, 2023 Category: Cardiology Authors: Shih-Ting Huang Tung-Min Yu Chia-Hsin Chen Yun-Chung Cheng Ya-Wen Chuang Cheng-Hsu Cheng Jia-Sin Liu Chih-Cheng Hsu Ming-Ju Wu Source Type: research
SGLT2 Inhibitors: The Next Blockbuster Multifaceted Drug?
Medicina (Kaunas). 2023 Feb 16;59(2):388. doi: 10.3390/medicina59020388.ABSTRACTSodium glucose cotransporter 2 inhibitor (SGLT2i) is a class of drugs that were originally intended for decreasing blood glucose in diabetes. However, recent trials have shown that there are other beneficial effects. Major clinical trials involving SGLT2i medications from 2015 to 2022 were reviewed using PUBMED search. Recent major SGLT2i landmark trials have demonstrated benefits for cardiovascular disease (reduce major adverse cardiovascular events (heart attack, stroke, cardiovascular death), hospitalization for heart failure, all-cause deat...
Source: Medicina (Kaunas) - February 25, 2023 Category: Universities & Medical Training Authors: Jonathan C H Chan Michael C Y Chan Source Type: research
